Capital International Inc. CA Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Capital International Inc. CA increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 70,605 shares of the biopharmaceutical company's stock after buying an additional 6,380 shares during the period. Capital International Inc. CA owned 0.06% of Regeneron Pharmaceuticals worth $50,294,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $36,000. Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Private Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on REGN shares. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating for the company in a report on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $949.60.

Regeneron Pharmaceuticals Stock Up 1.1 %

Regeneron Pharmaceuticals stock traded up $6.46 during mid-day trading on Thursday, reaching $594.31. 591,943 shares of the company's stock were exchanged, compared to its average volume of 718,029. The company has a market cap of $64.97 billion, a P/E ratio of 15.55, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a fifty day moving average of $640.41 and a 200-day moving average of $731.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $11.86 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.